Aspira Women’s Health Reports 15% Revenue Decline and Net Loss in Q2 2026

Aspira Women’s Health Inc. reported a decline in financial performance for the second quarter of 2026, with revenues totaling $2.046 million, a 15% decrease from $2.404 million in the same period last year. For the first half of 2026, the company generated $4.013 million in revenue, down 14% from $4.683 million in the first half of 2025. The decrease in revenue was attributed to a reduction in the volume of OvaSuite tests performed, which fell by 12% to 5,059 tests in the second quarter, compared to 5,728 tests in the prior year. The average unit price for OvaSuite tests also decreased, contributing to the overall revenue decline.

The company reported a net loss of $2.420 million for the second quarter, an improvement from a net loss of $2.666 million in the same quarter of 2025. For the first half of 2026, the net loss was $1.744 million, significantly reduced from $4.519 million in the first half of 2025. This reduction in losses was primarily due to a decrease in operating expenses, which fell by 11% to $2.966 million in the second quarter, compared to $3.344 million in the previous year. Notably, general and administrative expenses decreased by 13%, reflecting cost-cutting measures.

In terms of strategic developments, Aspira completed a private placement offering in June 2026, raising approximately $1.410 million through the issuance of 3,133,333 shares of common stock and accompanying warrants. This move is part of the company's ongoing efforts to secure additional funding to support its operations and product development. The company also continues to focus on expanding its product offerings, particularly in the areas of ovarian cancer and endometriosis diagnostics, with plans to introduce new tests and enhance existing ones.

Operationally, Aspira's workforce has been adjusted, with a reduced field sales headcount impacting test volumes. The company is actively working to improve its sales and marketing strategies to drive revenue growth. As of June 30, 2026, Aspira reported a working capital deficit of approximately $2.542 million and an accumulated deficit of $545.921 million. The company has indicated that it expects to continue incurring losses and negative cash flows for the remainder of 2026, raising concerns about its ability to sustain operations without additional financing.

Looking ahead, Aspira Women’s Health is focused on increasing test volumes and revenue through enhanced marketing efforts and partnerships. The company is also exploring various avenues for raising capital, including equity offerings and collaborations, to ensure it can meet its operational needs and continue its product development initiatives. However, there remains substantial doubt about the company's ability to continue as a going concern within the next year, contingent on its ability to generate sufficient revenue and secure additional funding.